Edited by: Ming Lei
Edited by: Ming Lei

New Findings r What is the central question of this study?
In a rat model of acute myocardial infarction (AMI), we investigated the effect of Tongxinluo (TXL) treatment. Does TXL activate autophagy and attenuate apoptosis of cardiomyocytes through the AMPK pathway to facilitate survival of cardiomyocytes and improve cardiac function? r What is the main finding and its importance?
Major findings are as follows: (i) TXL treatment preserved cardiac function and reduced ventricular remodelling, infarct size and inflammation in rat hearts after AMI; (ii) TXL treatment dramatically increased autophagy and inhibited apoptosis in myocardium; and (iii) the AMPK signalling pathway played a crucial role in mediating the beneficial effects of TXL.
Tongxinluo (TXL) has been demonstrated to have a protective role during ischaemia-reperfusion after acute myocardial infarction, but the long-term effects and underlying mechanisms are still unknown. The aim of this study was to investigate whether TXL could have an effect on apoptosis or autophagy of cardiomyocytes through the AMP-activated protein kinase (AMPK) pathway. Male Sprague-Dawley rats (n = 75) were randomly divided to sham, control, TXL (4 mg kg −1 day −1 orally), compound C (i.p. injection of 10 mg kg −1 day −1 ) and TXL + compound C groups. The extent of fibrosis, infarct size and angiogenesis were determined by pathological and histological studies. Four weeks after acute myocardial infarction, TXL treatment significantly increased ejection fraction, promoted angiogenesis in the peri-infarct region and substantially decreased fibrosis and the size of the infarcted area (P < 0.05). Treatment with TXL also increased AMPK/mTOR phosphorylation, upregulated expression of the autophagic protein LC3 and downregulated expression of the apoptotic protein Bax in the infarcted myocardium (P < 0.05). Addition of the AMPK inhibitor, compound C, counteracted these beneficial effects significantly (P < 0.05). The cardioprotective benefits of TXL against myocardial infarction are related to the inhibition of apoptosis and promotion of autophagy in rat hearts after acute myocardial infarction. This effect may occur through the AMPK signalling pathway.
Introduction
Acute myocardial infarction (AMI), caused primarily by the blockage of blood flow to the myocardial tissue, is becoming a leading cause of death worldwide (Mozaffarian et al. 2016) . Acute myocardial infarction causes death for many cardiomyocytes because they are deprived of oxygen during the blockage (De Celle et al. 2005) . These cells cannot regenerate, thus contributing to cardiac dysfunction, cardiac arrhythmia, heart failure and even sudden death (Powell, 2006) . Although substantial effort has been made to repair damaged myocardium, the recovery of cardiac function generally remains unsatisfactory (Zhao et al. 2006; Sürder et al. 2013) . Hence, new methods are still needed for improvement in the survival of cardiac cells, a critical issue for patients postinfarction.
Apoptosis and autophagy are important pathways that regulate cellular homeostasis and control cell survival and death (Cuervo, 2004; Hamacher-Brady et al. 2006) . Various studies have shown that autophagy can be either a pro-survival strategy or a pro-death strategy, which is determined by different situations (Matsui et al. 2007; Azad et al. 2008) . For example, autophagy can reduce apoptosis of cultured HL-1 cells subjected to simulated ischaemia-reperfusion, but can also promote apoptotic cell death in conditions of hypoxia and serum deprivation (Zhang et al. 2012b; Przyklenk et al. 2012) . Dysfunction in the autophagy pathway could be related to numerous cardiovascular diseases, such as cardiomyopathy (Shimomura et al. 2001) , atherosclerosis (Ouimet, 2013) and ischaemia-reperfusion injury (Cui et al. 2014) . However, the effect of autophagy in myocardial infarction is still controversial.
Tongxinluo (TXL), a widely used traditional Chinese medication, comprises extracts from 12 herbal medicines, including Radix ginseng, Buthus martensi, Hirudo, Eupolyphaga seusteleophage, Scolopendra subspinipes, Periostracum cicadae, Radix paeoniae rubra, Semen ziziphi spinosae, Lignum dalbergiae odoriferae, Lignum santali albi and Borneolum syntheticum. The chemical ingredients of TXL have been studied by using high-performance liquid chromatography and gas chromatography, and the major ingredients have been demonstrated to be peoniflorin, ginsenoside Rg1, ginsenoside Rb1, jujuboside A, jujuboside B, isoborneol and borneol (Chen et al. 2009; Zhang et al. 2009; Su et al. 2010) . Tongxinluo has been approved by the China State Food and Drug Administration for decades (Yu et al. 2016) . Tongxinluo is applied in multiple cardiovascular diseases, including atherosclerosis, angina pectoris and ischaemia-reperfusion injury, and it has been reported to have multiple cardioprotective effects, such as antioxidant, anti-inflammatory and antifibrotic effects (Wu et al. 2006; Zhang et al. 2009; Li et al. 2010) . We have shown previously that TXL pretreatment with a loading dose protects cardiomyocytes from myocardial no-reflow and reperfusion injury during early postoperative periods after AMI (Cheng et al. 2009; Li et al. 2010) ; however, it remains unclear whether TXL could facilitate the survival of myocardium or improve long-term cardiac function after AMI. Furthermore, no research has been published regarding the impact or underlying mechanisms of TXL on the regulation of apoptosis or autophagy in infarcted hearts.
Several publications have implicated the AMPK/mTOR pathway in multiple cellular processes, including energy metabolism (McGee & Hargreaves, 2008) , cell proliferation ) and cell differentiation . The AMPK/mTOR pathway also has critical effects on both apoptosis and autophagy, thereby affecting cell survival and death (Gong et al. 2016) . The AMPK/mTOR pathway has a protective effect in cardiac ischaemic diseases (Tian & Balschi, 2006) , but it is not yet clear whether this effect is related to the impact of TXL on the myocardium after AMI. Therefore, in this study we investigated the potential role of autophagy in cardiomyocyte apoptosis after AMI. We also explored whether TXL can activate autophagy and attenuate apoptosis of cardiomyocytes through the AMPK pathway to facilitate the survival of cardiomyocytes and improve cardiac function in long-term, postinfarcted rat hearts.
Methods
Ethical approval
All the procedures were approved by the Care of Experimental Animals Committee of Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China, with the project number 2013-5-120-GZR. All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health, USA (eighth edition, 2011).
Animal preparation
Seventy-five male Sprague-Dawley rats, weighing 190-220 g, were used in the present experiments. Animals were obtained from the animal breeding facility of the Fuwai Hospital and were housed individually in a temperature-controlled room at 25°C in the Animal Facility of the Department of Fuwai Hospital. Animals were kept under a 12 h-12 h light-dark cycle, with food and water ad libitum. Rats were transported to the experimental room and remained in their cages throughout the experiment.
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Tongxinluo preparation
Tongxinluo powder was obtained from Yiling Medical Research Institution (Shijiazhuang, China). The TXL ultrafine powder was dissolved in 0.9% saline. A detailed description of TXL and the preparation methods was given previously (Luo et al. 2015; Ma et al. 2015) .
Animal protocol
Rats were randomly assigned to one of the following five groups: sham-operated (sham); control (AMI); TXL treatment (4 mg kg −1 day −1 orally; TXL); compound C treatment (Abcam, Cambridge, UK; an AMPK inhibitor; I.P. injection at 10 mg kg −1 day −1 ; CC); or combined therapy of TXL and compound C (TXL + CC). Slow-release buprenorphine (Sigma, St Louis, IL, USA; 1 mg kg −1 ) was injected S.C. 2 h before surgery, which provides adequate analgesia for 3 days. Before starting the surgical procedures, rats were anaesthetized with an I.P. injection of pentobarbital sodium (Sigma, St Louis, IL, USA; 50 mg kg −1 ). To assess the level of consciousness by the degree of antinociception (lack of response to noxious stimuli) after the induction of general anaesthesia, we gently pinched the hindpaw of the animals and observed the musculoskeletal response and cardiovascular and respiratory function. All rats (except the sham group) were used to establish an AMI model by ligating the left anterior descending coronary artery, as described previously (Müller-Ehmsen, 2002) . Sham operations were performed by passing a suture around the left anterior descending coronary artery without ligation. Drugs were given once per day postoperatively for 4 weeks. Four weeks after the operation, rats were anaesthetized with pentobarbital sodium as mentioned above for echocardiographic assessment and then killed rapidly by cervical dislocation.
Echocardiographic assessment
Transthoracic echocardiography (Sonos 7500; Phillips; equipped with a 12 MHz phased-array transducer) was performed at 3 days and 4 weeks post-AMI. The hearts were recorded in two-dimensions and M-mode from the parasternal long-axis view at the papillary muscle level. Cardiac function and ventricular dimensions, including left ventricular end-diastolic dimension (LVEDd), left end-systolic dimension (LVESd), left ventricular fractional shortening (LVFS) and left ventricular ejection fraction (LVEF), were measured and calculated as described previously (Xu et al. 2011) . Briefly, LVEDd and LVESd were measured for at least three consecutive cardiac cycles. The LVFS was calculated as [(LVEDd − LVESd)/LVEDd] × 100%, and LVEF was calculated as [(LVEDd) 3 − (LVESd) 3 ]/(LVEDd) 3 ] × 100%. All measurements were made by an independent blinded sonographer.
Histological analysis
Heart tissues were fixed in 10% formalin and cut into 4-μm-thick paraffin sections at the mid-level of the left ventricle (LV). Inflammatory cell infiltration was evaluated by Haematoxylin and Eosin staining. The fibrotic area and infarct size were semi-quantified by Masson's trichrome staining and measured using Image-Pro-Plus software (Media Cybernetics, Rockville, MD, USA). The fibrotic area was measured as a percentage of the total LV [(fibrotic area/total LV area) × 100%]. At least five sections from each heart were stained and examined.
Immunohistochemical analysis of CD31
Myocardial tissue sections were obtained from peri-infarct regions of all rats at 4 weeks after AMI. To assess angiogenesis, immunohistochemistry was conducted on paraffin sections using polyclonal primary antibodies against CD31 (ab28364, Abcam, Cambridge, UK; 1:100 dilution).
TUNEL assay and immunofluorescence microscopy of LC3
A terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labelling (TUNEL) assay (1:9 dilution; Roche, Indianapolis, IN, USA) was performed as described previously (Xue et al. 2016) . For immunofluorescence microscopy, heart sections were fixed in 4% paraformaldehyde and then washed in PBS. Sections were incubated in sodium citrate buffer with 0.1% Triton X-100 for 20 min at 48°C and blocked with 10% normal goat serum in PBS with 0.25% Triton X-100 for 1 h. The sections were then incubated with rabbit anti-LC3 (4108, 1:200 dilution; Cell Signaling Technology, Danvers, MA, USA) for 3 h at room temperature, washed in PBS and incubated with the secondary antibody.
Western blot analysis
Proteins were extracted from peri-infarcted regions of the myocardium, and the protein concentrations were determined using a bicinchoninic acid (BCA) assay.
Into each lane of a 10% SDS-PAGE gel, 50 mg of protein was loaded and resolved using standard methods. The proteins were then transferred to nitrocellulose membranes (Life Technologies, Waltham, MA, USA) and blocked with 5% non-fat dry milk. The membranes were incubated with primary antibodies against Bax (2772, Cell signaling Technologies, Danvers, MA, USA), Cell Signaling Technologies). β-Actin was used as a loading control (1:1000 dilution; Zhongshanjinqiao, Beijing, China). Next, the membranes were incubated with peroxidase-conjugated secondary antibodies, diluted 1:5000. After washing, the membranes were visualized using electrochemiluminescence (ECL, Thermo Scientific, Rockford, IL, USA). Band intensities were quantified and calculated using standard densitometry methods.
Statistical analysis
The data were expressed as means ± SD. Analysis of variance and Student's unpaired t test were used to compare among groups and between two groups, respectively. Statistical analysis was conducted using SPSS Software (version 18.0; SPSS Inc., Chicago, IL, USA), and a P value <0.05 was considered statistically significant.
Results
Tongxinluo treatment increased ejection fraction and cardiac function
Cardiac function and left ventricular parameters were detected by echocardiography in all groups at 3 days and 4 weeks after AMI. The data at 3 days showed no significant differences between the treatment groups, indicating that the operation was performed successfully and consistently (Table 1 and Fig. 1 ). At 4 weeks post-AMI, a similar trend was observed in LVEDd and LVESd for all groups except sham. However, compared with other groups, TXL treatment significantly improved the LVEF and LVFS (P < 0.05). Compound C treatment, alone or in combination with TXL, produced no significant difference relative to the AMI group (Table 1 and Fig. 1 ). The LVEF was dramatically increased in the TXL group (53.03 ± 8.08%) compared with the AMI group (42.40 ± 7.69, P < 0.05), and no remarkable differences were observed in groups CC (42.35 ± 6.62%, P > 0.05) and TXL + CC (45.88 ± 4.67%, P > 0.05). Moreover, TXL treatment significantly increased LVFS (25.47 ± 2.95%) relative to the AMI group (18.31 ± 3.87%, P < 0.05) and the CC group (18.12 ± 3.37%, P < 0.05). These results indicate that TXL treatment effectively improves cardiac function and reduces cardiac remodelling. These beneficial effects could be attenuated by compound C.
Tongxinluo treatment reduced myocardial infarction, fibrosis and inflammation
Histological examination showed that TXL markedly increased the survival of myocardium and reduced inflammatory cell infiltration and fibrosis in the peri-infarct regions of hearts 4 weeks after AMI (Fig. 2 ).
Masson's trichrome staining was performed to investigate fibrosis and extracellular matrix accumulation of the whole heart and the peri-infarct region, respectively. As shown in Fig. 2A and C, thinning of the anterior walls, dilated LV chambers, severe fibrosis and large infarct size were apparent in the AMI group. These results were comparable for CC and TXL + CC groups. However, TXL treatment dramatically reduced chamber dilatation and the fibrotic area of the LV (21.11 ± 4.86%) relative to the AMI group (34.33 ± 5.78%, P < 0.05), the CC group (36.91 ± 6.78%, P < 0.05) and the TXL + CC group (33.62 ± 5.92%, P < 0.05; Fig. 2B ).
Haematoxylin and Eosin staining was performed to quantify the amount of inflammatory infiltration in the peri-infarct regions. Decreased inflammatory cells were found in the TXL group relative to all other groups, while no significant differences were observed between these other groups (Fig. 2D) .
Tongxinluo treatment increased angiogenesis in peri-infarct cardiomyocytes
The effect of TXL on angiogenesis in the peri-infarct region of hearts was measured using immunohistochemical analysis for CD31. Capillary density analysis, which is calculated as the number of capillaries per high-powered field (magnification ×400), showed a remarkable decrease in capillary density in infarcted hearts (AMI) compared with the sham group (9.40 ± 3.44; Fig. 3A and B) . In contrast, capillary density was remarkably increased in the TXL treatment group (9.20 ± 2.15) over the AMI group (3.00 ± 0.98, P < 0.05). No significant differences were found between the AMI group, the CC group (3.40 ± 1.85) and the TXL + CC group (4.00 ± 1.41). In addition, combined treatment with TXL and CC did not significantly change the number of capillaries compared with the sham group. Taken together, these results indicate that TXL treatment promotes vascularization, and this effect could be reversed using the AMPK inhibitor, compound C.
Tongxinluo treatment inhibited apoptosis of myocardial cells in infarcted hearts
Next, TXL and compound C were examined for an effect on the survival of myocardial cells in the infarcted hearts by staining tissues with TUNEL (green) and immunofluorescence labelling with of DNA with Fig. 4A , the number of apoptotic cells in the peri-infarcted regions collected from the AMI group was larger than for the sham group. Tongxinluo treatment decreased the number of apoptotic cells compared with the sham group. However, the percentage of apoptotic cells in hearts from rats treated with compound C showed no difference from the AMI group. Animals treated with the combination of TXL and compound C showed no significant difference compared with animals that were treated with compound C alone.
,6-diamidino-2-phenylindole (DAPI) (blue). As is shown in
Further analysis of apoptosis-related proteins was conducted by Western blot (Fig. 4B) . The anti-apoptotic protein, Bcl-2, was downregulated in the AMI group compared with the sham group. In contrast, Bax, which is a pro-apoptotic protein, increased significantly in untreated rats. Tongxinluo treatment significantly decreased expression of Bax and induced expression of 
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Bcl-2 relative to the other groups (P < 0.05). These effects were abrogated by compound C; thus, expression of these proteins was similar among the AMI, CC and TXL + CC groups ( Fig. 4C and D) .
Tongxinluo induced autophagy of myocardial cells in infarcted hearts
The effects of TXL and compound C on autophagy of cardiac cells after AMI was measured with co-immunofluorescent staining for LC3 (green) and DNA (DAPI; blue). LC3, which promotes autophagy, was used as an autophagy-specific marker. Expression of LC3 was decreased in infarcted hearts from the AMI group relative to the sham group. Tongxinluo treatment resulted in increased LC3 compared with untreated (AMI) specimens. However, the LC3-positive cells in infarcted hearts of animals treated with compound C were slightly reduced relative to those from animals that received no treatment. Combined compound C and TXL treatment revealed no apparent difference relative to compound C treatment alone (Fig. 5A ).
Further analysis by Western blot detected autophagy-related proteins, including LC3 and Beclin-1 (Fig. 5B) . The LC3II/LC3I ratio was significantly lower in the AMI group and significantly upregulated by TXL treatment compared with the sham group. Moreover, the effect of TXL was abrogated by compound C; thus, there was no significant difference in the LC3II/LC3I ratio between groups, with the exception of the TXL group ( Fig. 5C and D) . Notably, the expression of Beclin-1 showed no statistical differences (P > 0.05).
Tongxinluo treatment mediated the phosphorylation of AMPK pathway proteins
To determine a role for the AMPK signalling pathway in the effect of TXL on apoptosis and autophagy regulation, the AMPK inhibitor, compound C, was applied and the expression of key signalling proteins detected by Western blot (Fig. 6A) . As is shown in Fig. 6B , TXL treatment upregulated p-AMPK (phosphorylated AMPK) and downregulated p-mTOR (phosphorylated mTOR) relative to animals without treatment (P < 0.05). These changes in phosphorylation were blocked by the addition of compound C. However, the expression levels of AMPK and mTOR exhibited no obvious differences among groups.
Discussion
This study used an in vivo rat AMI model to investigate effect of TXL on autophagy and apoptosis in cardiomyocytes, explore the protective effects of TXL on infarcted hearts and elucidate the underlying mechanisms through which TXL may act. The results were as follows: (i) TXL treatment preserved cardiac function and reduced ventricular remodelling, infarct size and inflammation in rat hearts after an AMI; (ii) TXL treatment dramatically increased autophagy and inhibited apoptosis in the Fig. 1 . n = 5 for each group. * P < 0.05 versus AMI; # P < 0.05 versus TXL. myocardium; and (iii) the AMPK signalling pathway played a crucial role in mediating the beneficial effects of TXL. To our knowledge, this study is the first to clarify a pro-autophagic role for TXL in the long-term, postinfarct period in vivo and illustrate the potential signalling pathway.
In most cases, AMI is attributable to the disruption of a vulnerable atherosclerotic plaque or erosion of the coronary artery endothelium, leading to impairment of ejection fraction, myocardial necrosis, myocardial fibrosis, ventricular remodelling and an inflammatory response (Libby, 2013) . Previous studies have found that TXL treatment significantly decreased the no-reflow and infarct size after 90 min of ischaemia and 3 h of reperfusion in a pig model (Li et al. 2013) . Likewise, acute pretreatment with a single loading dose of TXL (50 mg kg −1 ) reduced no-reflow and ischaemia-reperfusion injuries in rat hearts, but the outcome of long-term TXL therapy is not clear (Li et al. 2010) . In the present study, oral therapy with TXL for 1 month after AMI markedly reduced the deterioration of cardiac function, with higher ejection fraction and a smaller infarct area. These data suggest that long-term therapy with TXL is beneficial for the recovery of LV dysfunction.
One of key reasons for structural or functional impairment after an AMI is the acute inflammatory response. This response harms the myocardium and leads to the death of cardiac cells, fibrosis and ventricular remodelling (Bekkers et al. 2010) . Leucocytes, mainly neutrophils, are recruited and accumulate in injured myocardium after infarction, causing the release of various inflammatory factors, which lead to further cellular damage (Tsujioka et al. 2009; Jung et al. 2013) . Loss of infarcted myocardium results in fibrosis, ventricular wall thinning, ventricular dilatation, eventual cardiac remodelling and potential heart failure Q. Li and others . We found that TXL reduced the amount of neutrophil infiltration in the peri-infarcted region of rat hearts 4 weeks after AMI, as shown by Haematoxylin and Eosin staining. Furthermore, TXL treatment dramatically reduced fibrosis in infarcted hearts and reduced ventricular dilatation, as reflected by the significant increase in LVFS in Table 1 . These findings are consistent with several previous studies. Tongxinluo was shown to have an anti-inflammatory effect in stabilizing vulnerable plaques through the inhibition of expression of pro-inflammatory cytokines, including matrix metalloproteinase 1, nuclear factor-κB, tumour necrosis factor-α, interleukin-1 and intercellular adhesion molecule 1 (Zhang et al. 2008) . Furthermore, proteins of the matrix metalloproteinase family take part in the digestion of collagen and could be upregulated by TXL, thus inhibiting collagen synthesis, extracellular matrix deposition and myocardial fibrosis ). These findings might explain the antifibrotic and anti-inflammatory effects we observed with TXL treatment.
Neovascularization is critical for cardiac tissue repair; however, it is usually restricted by the harsh environment present after AMI (Meloni et al. 2010) . Increased vascular density could increase blood perfusion to the peri-infarct region, which might be responsible, in part for improvement of left ventricular function (Wang et al. 2004) . In previous studies, TXL was found to promote angiogenesis in rats with ischemic stroke and mice with pressure overload-induced heart failure (Chang et al. 2012; Wang et al. 2014) . Likewise, we found that TXL increased the capillary density in rat hearts after AMI by examining the expression of CD31, a marker on the surface of vascular endothelial cells that can indicate angiogenesis. The results, taken together, suggest that TXL can promote angiogenesis in chronically ischaemic hearts. We investigated how TXL exerts its cardioprotective effects and concluded that TXL could be both pro-autophagic and anti-apoptotic, thus protecting against ischaemic damage. Both TUNEL immunofluorescence staining and Western blot analysis of apoptosis-related proteins showed that TXL treatment significantly reduced apoptosis relative to the control group, suggesting an anti-apoptotic role. In contrast, TXL appears to exhibit a pro-autophagic effect, because the TXL group exhibited a clear increase in LC3-positive cells compared with the other tested groups. Furthermore, the ratio of LC3II/LC3I expression, as measured by Western blot, was also increased with TXL treatment. LC3, also known as Atg8 in mammals, is located on the membrane of the autophagosome and is considered a reliable marker of autophagy (Xiao et al. 2011) . The cytosolic precursor, LC3, is cleaved to produce LC3I, which activates and converts to LC3II during autophagosome formation. Hence, the LC3II/LC3I ratio is another important marker of autophagy (Przyklenk et al. 2012) . Some studies have demonstrated that autophagy is significantly upregulated in ischaemic diseases. Matsui et al. (2007) observed a robust increase in the LC3II/LC3I ratio after 20 min of coronary artery occlusion in mice. Data obtained by Aránguiz-Urroz et al. (2011) showed an increase in autophagosome formation in rat cardiac fibroblasts. Our study further supports an increase in autophagy in rat hearts after AMI. Autophagosome formation is further upregulated by TXL.
Another important autophagic protein is Beclin-1; however, our study revealed no significant differences in Beclin-1 expression in the tested groups. Numerous factors could affect the expression of Beclin-1, including Bax, Bcl-xL and class III Phosphatidylinositol-3 Kinase (PI3K) (Huang et al. 2005) . For example, proteins of the Bcl-2 family have a crucial effect on the crosstalk between apoptosis and autophagy. Bcl-2 could bind to Bax and Beclin-1 to inhibit apoptosis and autophagy activation, respectively. In fact, an increase in Bcl-2 was found to be associated with decreased levels of Beclin in PC12 cells exposed to oxygen-glucose deprivation and reperfusion (Salminen et al. 2013) . Moreover, there was little change of Beclin expression in endothelial cells and mesenchymal stem cells in ischaemia-reperfusion injury (Cui et al. 2014; Li et al. 2014) . Thus, the increase of Bcl-2 seen in our study might inhibit Beclin-1 expression, which counteracts the elevation of Beclin-1 expression through autophagy signalling, resulting in no net difference in Beclin-1 expression levels.
The fate of a cell is determined through a well-controlled process, in which apoptosis and autophagy both take part. The interplay between these two pathways is complex and critical (Eisenberg-Lerner et al. 2009 ). Autophagy could have a pro-survival effect by inhibiting apoptosis in several different sets of conditions, sometimes resulting in cell death either through co-operation with apoptosis or as a supplement when apoptosis is defective (Eisenberg-Lerner et al. 2009 ). There is no general agreement on whether the activation of autophagy is protective and how it interacts with apoptosis in ischaemic heart diseases. One study revealed that induction of autophagy inhibits apoptotic cell death and is beneficial for cardiac function during ischaemia (Hoshino et al. 2012) . Conversely, suppression of Beclin-1 by RNA interference was shown to promote survival of cardiomyocytes subjected to simulated ischaemia-reperfusion (Valentim et al. 2006) . Although much attention has been focused on autophagy research, none of these studies report the impact of TXL on the regulation of autophagy and its interaction with apoptosis in the postinfarct period. In our study, we found that autophagy functions antagonistically to apoptosis during ischaemia in rat hearts after an AMI, indicating that it blocks apoptotic cell death and promotes cell survival. The pro-autophagic and anti-apoptotic effect of TXL in the myocardium is likely to be the mechanism through which TXL preserves cardiac function in long-term, postinfarcted rat hearts.
The AMPK inhibitor, compound C, was used throughout this investigation to determine a role for the AMPK pathway in the effects of TXL on infarcted hearts. AMPK is known as an important receptor that enables cells to sense changes in energy availability, while mTOR functions as a vital signalling complex in many cellular processes (Niesler et al. 2007; Kim et al. 2011) . The AMPK pathway has been reported in several previous studies to have a role in mediating the cardioprotective effects of multiple therapies for ischaemic heart diseases. For example, thyroid hormone, which is associated with AMPK activation, was shown to improve the mechanical performance in postinfarcted myocardium (Mourouzis et al. 2013) . Our previous studies have found that atorvastatin effectively activated the AMPK pathway to enhance stem cell survival during hypoxic and serum-deprivation conditions (Zhang et al. 2012a) . In the present study, p-AMPK protein levels were markedly increased, whereas p-mTOR protein levels were decreased with TXL treatment (Fig. 6 ). These changes were attenuated by treatment with compound C, which counteracted the improvement of cardiac function and the anti-inflammatory, antifibrotic, pro-angiogenic effects of TXL (Figs 1-3) .
AMPK and mTOR both take part in the regulation of autophagy and apoptosis (Eisenberg-Lerner et al. 2009 ). AMPK senses the absence of energy or nutrients via an increased AMP/ATP ratio, promoting autophagy by stimulating tuberous sclerosis complex 1/2 (TSC1/TSC2) activity through its phosphorylation. mTOR is negatively regulated by TSC1/TSC2; thus, mTOR is inactivated by AMPK, and autophagy is induced (Ding et al. 2007) . mTOR is a central molecule in various signalling pathways that mediate apoptosis (Wouters & Koritzinsky, 2008) . For example, reactive oxygen species could inactivate AMPK and activate mTOR, leading to upregulation of reactive oxygen species-generating NADPH oxidase 2 protein and its regulatory proteins, thereby inducing apoptosis (Zhang et al. 2017) . The present study confirmed that TXL treatment exerts pro-autophagic and anti-apoptotic effects when administered daily for 4 weeks after AMI. Compound C attenuated these effects significantly (Figs 4 and 5) . We posit that TXL inhibits AMPK phosphorylation and reduces mTOR phosphorylation, leading to the activation of autophagy and reduction of apoptosis.
In conclusion, our study demonstrated that chronic TXL treatment could significantly promote autophagy and inhibit apoptosis, preserving the myocardium and promoting proper cardiac function and morphology of infarcted rat hearts through activation of the AMPK signalling pathway. Despite the development of therapies for AMI over the past decades, it remains a leading cause of morbidity and mortality worldwide. The cardioprotective effects of TXL provide a new pharmacological treatment option for AMI that merits further investigation.
